Table 2.
Baseline and clinical characteristics of warfarin users and nonusersa
| Characteristic | Nonusers (N=131) | Warfarin users (N=154) | p-value |
|---|---|---|---|
| Age (years) | 68 (55, 77) | 76 (68, 82) | <0.0001 |
| Male | 53 (40) | 86 (56) | 0.001 |
| Ever smoker | 20 (15) | 22 (14) | 0.82 |
| Body mass index, kg/m2 | 29 (26, 32) | 26 (25, 30) | 0.004 |
| Metabolic markers | |||
| Fasting blood glucose, mg/dL | 97 (87, 111) | 103 (90, 121) | 0.08 |
| Glycated hemoglobin, % | 6 (6.0, 6.2) | 6 (6.0, 6.4) | 0.61 |
| AST, U/L | 22 (17, 27) | 22 (18, 25) | 0.82 |
| ALT, U/L | 19 (14, 26) | 19 (15, 24) | 0.86 |
| Albumin, g/dL | 4.1 (3.9, 4.3) | 4.0 (3.7, 4.2) | 0.0002 |
| Cholesterol markers, mg/dL | |||
| LDL-C | 118 (100, 146) | 108 (91, 120) | 0.0002 |
| HDL-C | 47 (40, 58) | 40 (36, 50) | 0.0001 |
| Triglycerides | 133 (91, 202) | 136 (86, 188) | 0.81 |
| Total cholesterol, mean±SD | 204±42 | 184±40 | <0.0001 |
| Cardiac parameters | |||
| Systolic blood pressure, mean±SD, mm Hg | 138±20 | 140±21 | 0.43 |
| Diastolic blood pressure, mm Hg | 80 (74, 90) | 80 (73, 89) | 0.33 |
| CHADS2 stroke risk | <0.0001 | ||
| score | |||
| 0 | 46 (35) | 13 (9) | |
| 1 | 36 (27) | 48 (31) | |
| ≥2 | 49 (37) | 93 (60) | |
| Years followed (IQR) | 6.1 (5.0, 7.4) | 2.5 (1.3, 4.3) | <0.0001 |
Notes:
a
Continuous data are presented as median (IQR), unless otherwise noted, and categorical date are presented as N (%).
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; HDL-C, high-density lipoprotein-cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein-cholesterol; SD, standard deviation.